-
Product Insights
Hypertriglyceridemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hypertriglyceridemia Clinical Trial Report Overview A total of 701 Hypertriglyceridemia clinical trials were conducted as of December 2023. The Hypertriglyceridemia clinical trial report provides a comprehensive understanding of the Hypertriglyceridemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Sector Analysis
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain...
-
Sector Analysis
Dyslipidemia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Dyslipidemia Market Report Overview The dyslipidemia market size across the 7MM was valued at $5.56 billion in 2022 and the market will achieve a CAGR of more than 10% during 2022-2032. The growth is attributed to the improved awareness about the health risks associated with dyslipidemia and growing efforts in screening and diagnosis are expected to lead to timely diagnosis of patients with this condition. Dyslipidemia Market Outlook, 2022-2032 ($ Billion) Buy Full Report to Know More About the Dyslipidemia...
-
Sector Analysis
Dyslipidemia Epidemiology Analysis and Forecast to 2032
Dyslipidemia Epidemiology Analysis Report Overview In the 7MM, there were 287,608,383 diagnosed prevalent cases of Dyslipidemia in 2022. The cases are expected to achieve an AGR of less than 1% during the period 2022-2032. The following are some of the key highlights of the Dyslipidemia epidemiology analysis report: Of the 7MM, the US is expected to have the highest number of total prevalent cases, and Italy will have the lowest number of total prevalent cases of dyslipidemia in 2032. In...
-
Sector Analysis
Painful Diabetic Neuropathy Epidemiology Analysis and Forecast to 2031
Painful Diabetic Neuropathy Market Report Overview The total prevalent cases of Painful Diabetic Neuropathy (PDN) were 7,472,695 cases in the seven major markets (7MM) in 2021 and are expected to achieve an AGR of more than 1% during 2021-2031. Diabetic neuropathy refers to a variety of syndromes that differ in clinical course, distribution, and fiber involvement. Symptoms of diabetic neuropathy vary widely from patient to patient, and some patients with diabetic neuropathy have no symptoms. The PDN market research report...
-
Sector Analysis
EpiCast Report: Dyslipidemia – Epidemiology Forecast to 2025
Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease (CVD), and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial The clinical diagnostic criteria for dyslipidemia and serum lipid abnormalities vary across countries and depend on the disease treatment and management guidelines that are followed in each country. Guidelines for the detection, evaluation, treatment, and management of dyslipidemia, as well...
-
Product Insights
Tay-Sachs Disease Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Tay-Sachs Disease Global Clinical Trials Review, H2, 2016" provides an overview of Tay-Sachs Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Tay-Sachs Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Becker Muscular Dystrophy Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Becker Muscular Dystrophy Global Clinical Trials Review, H2, 2016" provides an overview of Becker Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Becker Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2016" provides an overview of Glycogen Storage Disorders (GSD) clinical trials scenario. This report provides top line data relating to the clinical trials on Glycogen Storage Disorders (GSD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016" provides an overview of Alpha- Antitrypsin Deficiency clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha- Antitrypsin Deficiency. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.